Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01111188

Recruitment Status : Terminated

First Posted : April 27, 2010

Last Update Posted : June 27, 2019

Sponsor:

Collaborators:

Millennium Pharmaceuticals, Inc.

Pfizer

Information provided by (Responsible Party):

Weill Medical College of Cornell University

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Terminated
Actual Primary Completion Date :	February 26, 2013
Actual Study Completion Date :	April 12, 2019

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Martin P, Ruan J, Furman R, Rutherford S, Allan J, Chen Z, Huang X, DiLiberto M, Chen-Kiang S, Leonard JP. A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma. Leuk Lymphoma. 2019 Dec;60(12):2917-2921. doi: 10.1080/10428194.2019.1612062. Epub 2019 May 23.

To Top